Quality of Life in Prostate Cancer Patients Undergoing Daily Adaptive Versus Non-Adaptive Radiation Therapy Utilizing A 1.5 Tesla MR-Linac. Int J Radiat Oncol Biol Phys 2023 Oct 01;117(2S):S114-S115
Date
10/03/2023Pubmed ID
37784299DOI
10.1016/j.ijrobp.2023.06.445Abstract
PURPOSE/OBJECTIVE(S): Using adaptive radiation therapy (ART) physicians can re-contour normal organs (such as bladder and rectum) before each fraction. While ART may result in more reliable dosimetry to regional organs at risk, the process is time consuming and more expensive than non-ART. We evaluated differences in patient reported quality of life (PR-QOL) between daily ART and non- ART.
MATERIALS/METHODS: Patients with prostate cancer from 3 centers in the Netherlands and United States were treated using a 1.5 Tesla MR Linear accelerator. Patients consented to the Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (MOMENTUM, NCT04075305) between 2019 and 2022. PR-QOL was prospectively collected using the EORTC QLQ-C30 and PR-25 at baseline (before RT), and at 3 and 6 months after RT. Patients without complete QOL data were excluded. QOL differences were compared between patients undergoing daily ART vs. non-ART. A linear mixed effect model was performed to account for repeated measurements. Analyses were performed using R Studio.
RESULTS: One hundred thirty-six patients underwent RT with QOL were analyzed. Median follow up was 13 months (6-26 months). Patients were treated without daily ART (n = 94) or with daily ART (n = 42). The median age was 70 (range 53-83) years and 65.4% had intermediate risk disease, 35% of patients received hormonal therapy. Fractionation schedules included 36 Gy/6 (n = 16), 36.25 Gy/5 (n = 103), 60 Gy/20 (n = 6), 62 Gy/20 (n = 8), and 70 Gy/28 (n = 3). Compared to baseline scores, EORTC QLQ C30 diarrhea scores at 6 months post-treatment were significantly worse for patients treated without daily ART compared to those treated with daily ART (p < 0.05). Other QLQ PR25 bowel scores were not significantly different at 3 or 6 months. Both PR25 urinary and treatment-related symptoms were improved with daily ART compared to non-ART at the 3 (p < 0.001 and p < 0.01, respectively) and 6 (p < 0.01 and p < 0.001, respectively) month time points. Magnitude of improvements can be found in Table 1.
CONCLUSION: Among prostate cancer patients treated using 1.5 Tesla MRI-guided RT, daily ART was associated with improved PR-QOL in urinary and bowel domains compared to non-ART. These hypotheses generating preliminary results provide the first indications (to our knowledge) that adapting contours to daily anatomy may improve short-term urinary and bowel PR-QOL. Updated results will be presented at ASTRO 2023.
Author List
Ponce SEB, Daamen LA, Van der Voort vanZyp J, Westerhoff JM, Pos FJ, Christodouleas JP, Choudhury A, van der Heide U, Lawton CAF, Straza MW Jr, Bedi M, Paulson ES, Nasief HG, Li A, Verkooijen H, Tree A, Hall WAAuthors
William Adrian Hall MD Professor in the Radiation Oncology department at Medical College of WisconsinEric Paulson PhD Chief, Professor in the Radiation Oncology department at Medical College of Wisconsin
Michael W. Straza MD, PhD Assistant Professor in the Radiation Oncology department at Medical College of Wisconsin
